Swiss National Bank
EWTX icon

Swiss National Bank’s Edgewise Therapeutics EWTX Stock Holding History

Swiss National Bank’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.93M Sell
96,800
-7,100
-7% -$245K ﹤0.01% 1572
2026
Q1 		$3.27M Hold
103,900
– – ﹤0.01% 1588
2025
Q4 		$2.58M Buy
103,900
+2,000
+2% +$40.1K ﹤0.01% 1740
2025
Q3 		$1.65M Buy
101,900
+11,900
+13% +$169K ﹤0.01% 1941
2025
Q2 		$1.18M Buy
90,000
+7,400
+9% +$107K ﹤0.01% 2068
2025
Q1 		$1.82M Buy
82,600
+9,000
+12% +$236K ﹤0.01% 1821
2024
Q4 		$1.97M Hold
73,600
– – ﹤0.01% 1866
2024
Q3 		$1.96M Hold
73,600
– – ﹤0.01% 1869
2024
Q2 		$1.33M Buy
73,600
+6,300
+9% +$110K ﹤0.01% 2028
2024
Q1 		$1.23M Buy
67,300
+17,200
+34% +$273K ﹤0.01% 2115
2023
Q4 		$548K Buy
+50,100
New +$352K ﹤0.01% 2455

Other funds holding EWTX

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Paradigm Biocapital Advisors
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jupiter Topco
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Swiss National Bank's EWTX Position: Q2 2026 in Review

Swiss National Bank reduced its Edgewise Therapeutics (EWTX) stake by 6.8% in Q2 2026, selling an estimated $245K and leaving 96,800 shares worth $3.93M. The position accounts for ﹤0.01% of the portfolio, ranked #1572.

Swiss National Bank first reported a position in EWTX in Q4 2023 and has held it in 11 quarters since. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Swiss National Bank held 96,800 shares of Edgewise Therapeutics worth $3.93M as of Q2 2026.
  • Swiss National Bank sold 7,100 Edgewise Therapeutics shares in Q2 2026, an estimated $245K.
  • Edgewise Therapeutics made up ﹤0.01% of Swiss National Bank's portfolio in Q2 2026, its #1572 holding.
  • Swiss National Bank first reported a position in Edgewise Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.